IPCA Laboratories Quarterly Results for Trading Insights
In Mar 2026, IPCA Laboratories (IPCALAB) reported revenue ₹2,482 Cr and net profit ₹307 Cr — revenue +9.2% YoY. View IPCA Laboratories yearly highs lows for the annual high/low range and current price position.
IPCALAB Quarterly Results — Revenue, Profit & EPS Highlights
IPCA Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit IPCA Laboratories share price today.
- Revenue of ₹2,482 Cr in Mar 2026 (-11.8% vs Jun 2026, +9.2% vs Mar 2025)
- Net Profit of ₹307 Cr in Mar 2026 (-27.6% vs Jun 2026, +379.7% vs Mar 2025)
- EBITDA of ₹532 Cr in Mar 2026 (-23.5% vs Jun 2026)
- Operating Margin of 18.0% in Mar 2026 (-6.0pp vs Jun 2026)
- Earnings Per Share of ₹13.31 in Mar 2026 (-16.0% vs Jun 2026)
IPCA Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
IPCALAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,482 | 2,813 | 2,584 | 2,273 | 2,342 | -11.8% | 9.2% |
| Net Profit (₹ Cr) | 307 | 424 | 281 | 64 | 233 | - | - |
| EBITDA (₹ Cr) | 532 | 695 | 515 | 250 | 449 | - | - |
| EPS (₹) | 13.31 | 15.84 | 11.14 | 2.67 | 9.19 | - | - |
| Operating Margin (%) | 18.0% | 24.0% | 19.0% | 10.0% | 18.0% | - | - |
IPCALAB Share Price Trend — 1-Year Movement Across Quarterly Results
IPCA Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse IPCALAB institutional holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
IPCALAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
IPCA Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores